Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctnm · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) measures how much investors pay for each dollar of the company's trailing earnings. CTNM's current PE ratio of N/A is calculated by dividing its stock price of $11.23 by its TTM earnings per share of -$1.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Contineum Therapeutics, Inc. Class A Common StockYou CTNM | $420M | N/A | — | -$1.57 |
 AC Immune S.A. ACIU | $227M | N/A | — | -$0.70 |
 Aldeyra Therapeutics, Inc. ALDX | $106M | N/A | — | -$0.56 |
 Amarin Corporation plc AMRN | $294M | N/A | — | -$1.87 |
 Alto Neuroscience, Inc. ANRO | $637M | N/A | — | -$2.19 |
 Candel Therapeutics, Inc. CADL | $467M | N/A | — | -$0.72 |
 Capricor Therapeutics, Inc. CAPR | $1.2B | N/A | — | -$2.26 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.17 | — | |
2024-12-31 FY2024 | — | $-1.63 | — | |
2023-12-31 FY2023 | 17.03x | $0.90 | — | |
2022-12-31 FY2022 | — | $-0.97 | — | |
2021-12-31 FY2021 | — | $-1.15 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) measures how much investors pay for each dollar of the company's trailing earnings. CTNM's current PE ratio of N/A is calculated by dividing its stock price of $11.23 by its TTM earnings per share of -$1.57.
Frequently asked questions
CTNM pe ratio · 6 questionsCTNM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $11.23 and TTM EPS of -$1.57. Data sourced from Financial Modeling Prep via CTNM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Contineum Therapeutics, Inc. Class A Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08